Indaptus Therapeutics regains Nasdaq minimum bid price compliance

Indaptus Therapeutics, Inc.

Received Nasdaq notice on July 14, 2025 that closing bid price was ≥$1.00 for 10 consecutive business days (June 27-July 11, 2025).
Previously reported non-compliance on January 31, 2025; had until July 30, 2025 to regain compliance.
Nasdaq considers the bid price deficiency matter now closed.
Regaining compliance removes imminent delisting risk from The Nasdaq Capital Market.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.